Apr 6, 2026 07:10AM Pharvaris B.V. (PHVS) PT Lowered at RBC Capital; 'CHAPTER-3 Pivotal Topline In Focus For 3Q'

Apr 2, 2026 04:35PM Oppenheimer on Pharvaris B.V. (PHVS): runway sufficient to support ops through key milestones

Mar 20, 2026 06:51AM Pharvaris publishes hereditary angioedema drug study results in The Lancet

Mar 18, 2026 09:21AM RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'

Mar 11, 2026 06:50AM Pharvaris publishes study validating patient outcomes in hereditary angioedema

Mar 9, 2026 05:10AM RBC Capital Starts Pharvaris B.V. (PHVS) at Outperform

Mar 2, 2026 06:55AM Pharvaris presents deucrictibant data at allergy conference

Jan 22, 2026 06:42AM H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS)

Jan 12, 2026 06:50AM Pharvaris expects pivotal HAE study data in third quarter 2026

Dec 4, 2025 06:55AM Pharvaris B.V. (PHVS) PT Raised to $39 at Guggenheim

Dec 3, 2025 02:49PM Pharvaris B.V. (PHVS) PT Raised to $38 at Leerink Partners

Dec 3, 2025 11:44AM Pharvaris B.V. (PHVS) PT Raised to $30 at BofA Securities

Dec 3, 2025 06:50AM Pharvaris reports positive results from HAE treatment study

Nov 21, 2025 07:05AM Pharvaris B.V. (PHVS) Stock Setup is Strong - Cantor Fitzgerald

Nov 19, 2025 04:26AM Pharvaris B.V.'s (PHVS) Improving Profile Can Send Shares Up >$30s - Citizens

Oct 23, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS)

Oct 15, 2025 06:06AM H.C. Wainwright Starts Pharvaris B.V. (PHVS) at Buy

Oct 8, 2025 04:16PM BofA Securities Upgrades Pharvaris B.V. (PHVS) to Neutral 'on potential label expansion for angioedema treatment'

Aug 13, 2025 04:07AM Pharvaris B.V. (PHVS) PT Lowered to $52 at Citizens JMP

Jul 10, 2025 11:17AM BofA Securities Reiterates Underperform Rating on Pharvaris B.V. (PHVS)

Jul 10, 2025 06:51AM Pharvaris delays RAPIDe-3 study results to Q4 2025

Jun 27, 2025 06:50AM Pharvaris (PHVS) to Present Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE

Jun 16, 2025 06:50AM Pharvaris (PHVS) Presents Data Highlighting the Potential for Deucrictibant

Jun 5, 2025 04:20AM Citizens JMP Reiterates Market Outperform Rating on Pharvaris B.V. (PHVS)

Jun 2, 2025 06:52AM Pharvaris (PHVS) Presents Data Supporting Ongoing Clinical Development of Deucrictibant

Apr 23, 2025 04:23AM Citizens JMP Reiterates Market Outperform Rating on Pharvaris B.V. (PHVS)

Apr 1, 2025 06:50AM Pharvaris (PHVS) Granted Orphan Designation to Deucrictibant in the EU

Mar 3, 2025 06:50AM Pharvaris (PHVS) Presents Long-Term Clinical Data of Deucrictibant

Mar 3, 2025 04:49AM Citizens JMP Reiterates Market Outperform Rating on Pharvaris B.V. (PHVS)

Feb 18, 2025 04:15AM JMP Securities Reiterates Market Outperform Rating on Pharvaris B.V. (PHVS)

Jan 31, 2025 04:40AM Pharvaris B.V. (PHVS) PT Raised to $55 at JMP Securities

Jan 13, 2025 06:52AM Pharvaris (PHVS) Outlines 2025 Strategic Priorities

Oct 16, 2024 06:51AM Pharvaris (PHVS) to Present Data Highlighting Deucrictibant for the Treatment of HAE

Oct 14, 2024 06:08AM Oppenheimer Reiterates Outperform Rating on Pharvaris B.V. (PHVS)

Oct 3, 2024 06:50AM Pharvaris (PHVS) Announces Data Highlighting Deucrictibant for the Treatment of HAE

Sep 19, 2024 09:33AM Jones Trading Starts Pharvaris B.V. (PHVS) at Buy

Sep 6, 2024 05:07AM Pharvaris B.V. (PHVS) PT Raised to $42 at Oppenheimer

Sep 5, 2024 06:50AM Pharvaris (PHVS) Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE

Sep 5, 2024 06:50AM Pharvaris (PHVS) Provides Business Update, Expands Development Program for Deucrictibant

Jul 3, 2024 05:54AM Pharvaris B.V. (PHVS) PT Raised to $38 at Oppenheimer